HC Wainwright reissued their buy rating on shares of Akero Therapeutics (NASDAQ:AKRO – Free Report) in a research note released on Monday morning, Benzinga reports. They currently have a $50.00 price objective on the stock. HC Wainwright also issued estimates for Akero Therapeutics’ Q2 2024 earnings at ($0.82) EPS, Q3 2024 earnings at ($0.87) EPS, […]